Sintilimab Combined With Chidamide in Treating Peripheral T Cell Lymphoma - Trial NCT04512534
Access comprehensive clinical trial information for NCT04512534 through Pure Global AI's free database. This Phase 2 trial is sponsored by Fudan University and is currently Recruiting. The study focuses on Peripheral T-cell Lymphoma. Target enrollment is 51 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Fudan University
Timeline & Enrollment
Phase 2
Nov 13, 2020
Sep 01, 2025
Primary Outcome
Progression Free Survival (PFS)
Summary
This is a single-center, single-arm, phase 2 study to evaluate the efficacy and safety of
 Anti-PD-1 antibody(Sintilimab) plus HDAC inhibitor(Chidamide) in patients with
 relapsed/refractory peripheral T-cell lymphoma (r/r PTCL).
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT04512534
Non-Device Trial